Collaborative Drug Discovery (CDD) celebrates its sixth anniversary today, having grown into the leading provider of web-based software that organizes research data and helps scientists advance new drug candidates more effectively. CDD software enables researchers to collaborate—appropriately and securely—with others in the global community.
CDD—originally a spin-out of Eli Lilly & Co.—is taking advantage of the widespread acceptance of its platform among academic researchers to expand into the commercial pharmaceutical market. With the addition of big pharma and government laboratories to the community, the company has brought on board Andrea Barry as senior director of business development to drive this growing commercial initiative.
“Andrea has proven herself to be game-changer,” said Barry Bunin, CEO of CDD. “She brought significant growth to MDL, SciTegic and Accelrys—the powerhouses of traditional software tools in the commercial market—so we are confident that she is the right person to rapidly expand our market share as we bring our web-based collaborative approach to large pharmaceutical prospects and customers.”
Andrea Barry was the Director of North American Sales for SciTegic prior to its merger with Accelrys, Inc. Her team was responsible for 2/3 of the global revenue for the company. Bunin continues: “One only hires superstars for these particularly key executive business development roles. We spent over a year before deciding Andrea was just the right fit. I am as interested in her ability to develop a community and strengthen a revolutionary brand as I am in her skills as a revenue builder. Anyone who has worked with her knows that Andrea has the uncanny ability to do both. That’s why she is here at CDD.”
Date: March 29, 2010
Source: Collaborative Drug Discovery
